https://doi.org/10.4081/cardio.2024.50

Evaluating serum galectin-3 binding protein as a diagnostic and prognostic biomarker in pulmonary arterial hypertension: a comparative study

Vol. 2 No. 4 (2024)
Published: December 30 2024
Pulmonary arterial hypertension (PAH), Galectin-3 Binding Protein (Gal-3BP), hemodynamic parameters, prognosis, hemodynamics
Abstract Views: 1484
PDF: 362
HTML: 1
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Arif Albulushi
dr.albulushi@gmail.com
Department of Adult Cardiology, National Heart Center, The Royal Hospital, Muscat, Oman.
Lama S. Alfehaid
College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Mosaad Alhussein
King Faisal Specialist Hospital and Research Center, Riyadh; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Amr Youssef
Division of Cardiology, University of Wisconsin-Madison, Madison, WI, United States.

Background: Pulmonary arterial hypertension (PAH) is a severe condition with poor prognosis, characterized by elevated pulmonary artery pressure that leads to right ventricular failure. Identifying reliable biomarkers, such as Galectin-3 Binding Protein (Gal-3BP), could enhance PAH diagnosis and prognosis due to Gal-3BP's involvement in inflammation and fibrosis.
Methods: This prospective cohort study included 260 participants, 130 diagnosed with PAH and 130 healthy controls, from a tertiary care center. Serum Gal-3BP, NT-proBNP, and other biomarkers were measured alongside regular cardiopulmonary assessments. Right heart catheterization assessed hemodynamic parameters, and survival was analyzed using Kaplan-Meier curves over a 2-year period.
Results: PAH patients exhibited significantly higher serum Gal-3BP levels (5.34 ± 2.45 μg/mL) than controls (2.15 ± 0.95 μg/mL, p<0.001), correlating with elevated pulmonary artery pressure and reduced cardiac output (p<0.001). Kaplan-Meier analysis indicated lower survival rates for patients with Gal-3BP levels above the median (p<0.0001). Female patients averaged 58 years, with a 69% female study population.
Conclusions: Gal-3BP is significantly elevated in PAH patients, correlating with disease severity and predicting survival, positioning it as a promising biomarker for PAH diagnosis and prognosis. Future studies should examine Gal-3BP's role in therapeutic response and refine its clinical application.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1. Li M, Pan W, Tian D, et al. Diagnostic value of serum galectin-3 binding protein level in patients with pulmonary arterial hypertension. Curr Vasc Pharmacol 2024;22:67-77. DOI: https://doi.org/10.2174/0115701611268078231010072521
2. Haigh S, Bordán Z, Sellers HG, et al. Galectin 3 secretion in pulmonary arterial hypertension. Physiology 2023;38:5732582. DOI: https://doi.org/10.1152/physiol.2023.38.S1.5732582
3. Sun Y-Y, Wang L, Liu J-M, Yuan P. Reply to Sun et al.: circGASP: a new clinical biomarker for idiopathic pulmonary hypertension? Am J Respir Crit Care Med 2022;205:254. DOI: https://doi.org/10.1164/rccm.202108-1905LE
4. Jain A. High circulating plasma soluble receptor for advanced glycation end-products in early COVID-19-associated acute respiratory distress syndrome: pathophysiological significance? Am J Respir Crit Care Med 2022;205:254-6. DOI: https://doi.org/10.1164/rccm.202108-1896LE
5. Bouzina H, Hesselstrand R, Rådegran G. Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension. Pulm Circ 2019;9:2045894019895446. DOI: https://doi.org/10.1177/2045894019895446
6. Tifi P, Pala B, Tempestini F, et al. 729 Biomarkers for early diagnosis of cardiac involvement in systemic sclerosis. Eur Heart J Suppl 2022;24:suac121-284. DOI: https://doi.org/10.1093/eurheartjsupp/suac121.284
7. Kostyunina DS, Pakhomov NV, Jouida A, et al. Transcriptomics and proteomics revealed sex differences in human pulmonary microvascular endothelial cells. Physiol Genomics 2024;56:194-220. DOI: https://doi.org/10.1152/physiolgenomics.00051.2023
8. Chida A, Sato H, Shintani M, et al. Soluble ST2 and N-terminal pro-brain natriuretic peptide combination - useful biomarker for predicting outcome of childhood pulmonary arterial hypertension. Circ J 2014;78:436-42. DOI: https://doi.org/10.1253/circj.CJ-13-1033
9. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010;7:1-8. Erratum in Curr Heart Fail Rep 2012;9:163. DOI: https://doi.org/10.1007/s11897-010-0004-x
10. Mocumbi AO, Thienemann F, Sliwa K. A global perspective on the epidemiology of pulmonary hypertension. Can J Cardiol 2015;31:375-81. DOI: https://doi.org/10.1016/j.cjca.2015.01.030
11. Hemnes A, Rothman AMK, Swift AJ, Zisman LS. Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension. Pulm Circ 2020;10;2045894020957234. DOI: https://doi.org/10.1177/2045894020957234
12. Carrigan P, Krahn T. Impact of biomarkers on personalized medicine. Handb Exp Pharmacol 2016;232:285-311. DOI: https://doi.org/10.1007/164_2015_24
13. Al-Naamani N, Palevsky HI, Lederer DJ, et al. Prognostic significance of biomarkers in pulmonary arterial hypertension. Ann Am Thorac Soc 2016;13:25-30. DOI: https://doi.org/10.1513/AnnalsATS.201508-543OC
14. Giansanti F, Capone E, Ponziani S, et al. Secreted Gal-3BP is a novel promising target for non-internalizing antibody-drug conjugates. J Control Release 2019;294:176-84. DOI: https://doi.org/10.1016/j.jconrel.2018.12.018
15. Gleissner CA, Erbel C, Linden F, et al. Galectin-3 binding protein, coronary artery disease and cardiovascular mortality: Insights from the LURIC study. Atherosclerosis 2017;260:121-9. DOI: https://doi.org/10.1016/j.atherosclerosis.2017.03.031
16. Lima T, Perpétuo L, Henrique R, et al. Galectin-3 in prostate cancer and heart diseases: a biomarker for these two frightening pathologies? Mol Biol Rep 2023;50:2763-78. DOI: https://doi.org/10.1007/s11033-022-08207-1
17. Cibor D, Szczeklik K, Brzozowski B, et al. Serum galectin 3, galectin 9 and galectin 3-binding proteins in patients with active and inactive inflammatory bowel disease. J Physiol Pharmacol 2019;70:95-104. DOI: https://doi.org/10.1093/ecco-jcc/jjy222.146
18. Rosenkranz S, Preston IR. Right heart catheterisation: best practice and pitfalls in pulmonary hypertension. Eur Respir Rev 2015;24:642-52. DOI: https://doi.org/10.1183/16000617.0062-2015
19. Razmjou S, Abdulnour J, Bastard JP, et al. Body composition, cardiometabolic risk factors, physical activity, and inflammatory markers in premenopausal women after a 10-year follow-up: a MONET study. Menopause 2018;25:89-97. DOI: https://doi.org/10.1097/GME.0000000000000951
20. Ramirez MF, Honigberg M, Wang D, et al. Protein biomarkers of early menopause and incident cardiovascular disease. J Am Heart Assoc 2023;12:e028849. DOI: https://doi.org/10.1161/JAHA.122.028849
21. Nair A, Pillai AJ, Nair N. Cardiovascular changes in menopause. Curr Cardiol Rev 2021;17:e230421187681. DOI: https://doi.org/10.2174/1573403X16666201106141811
22. Camilleri G, Borg M, Brincat S, et al. The role of cytokines in cardiovascular disease in menopause. Climacteric 2012;15:524-30. DOI: https://doi.org/10.3109/13697137.2012.700743
23. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009;230:160-71. DOI: https://doi.org/10.1111/j.1600-065X.2009.00794.x

How to Cite



Evaluating serum galectin-3 binding protein as a diagnostic and prognostic biomarker in pulmonary arterial hypertension: a comparative study. (2024). Global Cardiology, 2(4). https://doi.org/10.4081/cardio.2024.50
Copyright (c) 2024 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.